Dane, A, Klein Gebbink, AS, Brugma, JD, Degrassat-Théas, A, Hug, MJ, Houlind, MB et al.. Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices. Appl Health Econ Health Policy. 2023; :. doi: 10.1007/s40258-023-00832-6. PubMed PMID:37751107 .
Kochar, N, Ip, S, Vardanega, V, Sireau, NT, Fineberg, NA. A cost-of-illness analysis of the economic burden of obsessive-compulsive disorder in the United Kingdom. Compr Psychiatry. 2023;127 :152422. doi: 10.1016/j.comppsych.2023.152422. PubMed PMID:37713953 .
Mayer-Hamblett, N, Clancy, JP, Jain, R, Donaldson, SH, Fajac, I, Goss, CH et al.. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective. Lancet Respir Med. 2023; :. doi: 10.1016/S2213-2600(23)00297-7. PubMed PMID:37699421 .
Lo Cicero, S, Castelli, G, Blaconà, G, Bruno, SM, Sette, G, Pigliucci, R et al.. L1077P CFTR pathogenic variant function rescue by Elexacaftor-Tezacaftor-Ivacaftor in cystic fibrosis patient-derived air-liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients. Respir Res. 2023;24 (1):217. doi: 10.1186/s12931-023-02516-0. PubMed PMID:37674160 PubMed Central PMC10483775.
Meregaglia, M, Malandrini, F, Angelini, S, Ciani, O. The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022. Appl Health Econ Health Policy. 2023; :. doi: 10.1007/s40258-023-00827-3. PubMed PMID:37659000 .
Hu, H, Lin, G, He, F, Liu, J, Jia, R, Li, K et al.. Design, synthesis, and biological evaluation of carbonyl-hydrazine-1-carboxamide derivatives as anti-hepatic fibrosis agents targeting Nur77. Bioorg Chem. 2023;140 :106795. doi: 10.1016/j.bioorg.2023.106795. PubMed PMID:37657195 .
Arabloo, J, Azari, S, Gorji, HA, Rezapour, A, Alipour, V, Ehsanzadeh, SJ et al.. Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review. Eur J Clin Pharmacol. 2023; :. doi: 10.1007/s00228-023-03557-6. PubMed PMID:37656182 .
Fishman, J, Wilson, K, Drzewiecka, A, Pochopień, M, Dingli, D. The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA. J Comp Eff Res. 2023;12 (10):e230055. doi: 10.57264/cer-2023-0055. PubMed PMID:37655691 .
Luo, S, Xie, C, Lin, N, Lin, D, Gu, D, Lin, S et al.. Cost-effectiveness analysis of an orphan drug-tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing. Melanoma Res. 2023; :. doi: 10.1097/CMR.0000000000000919. PubMed PMID:37650713 .
Enya, K, Lim, Y, Sengoku, S, Kodama, K. Increasing orphan drug loss in Japan: Trends and R&D strategy for rare diseases. Drug Discov Today. 2023;28 (10):103755. doi: 10.1016/j.drudis.2023.103755. PubMed PMID:37648019 .
Balkhi, B, Almuaither, A, Alqahtani, S. Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union. Saudi Pharm J. 2023;31 (9):101738. doi: 10.1016/j.jsps.2023.101738. PubMed PMID:37638213 PubMed Central PMC10458326.
Palcau, AC, Brandi, R, Mehterov, NH, Botti, C, Blandino, G, Pulito, C et al.. Exploiting Long Non-Coding RNAs and Circular RNAs as Pharmacological Targets in Triple-Negative Breast Cancer Treatment. Cancers (Basel). 2023;15 (16):. doi: 10.3390/cancers15164181. PubMed PMID:37627209 PubMed Central PMC10453179.
Getaneh, Y, Getnet, F, Ning, F, Rashid, A, Liao, L, Yi, F et al.. HIV-1 Disease Progression and Drug Resistance Mutations among Children on First-Line Antiretroviral Therapy in Ethiopia. Biomedicines. 2023;11 (8):. doi: 10.3390/biomedicines11082293. PubMed PMID:37626789 PubMed Central PMC10452141.
Vannucchi, AM, Guglielmelli, P. Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms: Friend and Enemy, Depending on Circumstances. JACC CardioOncol. 2023;5 (4):469-471. doi: 10.1016/j.jaccao.2023.07.001. PubMed PMID:37614589 PubMed Central PMC10443195.
Wang, Y. Catalyst Pharms., Inc. v. Becerra: When the Food and Drug Administration Repeatedly Ignores the Plain Language of the Orphan Drug Act (ODA). J Law Health. 2023;36 (2):139-158. . PubMed PMID:37585550 .
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.